The decoction from a tumbler made of heartwood of the Indian kino tree (Asana, Pterocarpus marsupium, PM) was a remedy for diabetes mellitus in Ayurveda. Diabetes mellitus is a one of the lifestyle-related diseases that finally leads to the induction of fatal diseases such as arterial sclerosis and cerebral infarction. In this study, effects on blood fluidity was investigated using extract obtained from the heartwood of PM. Oral administration of the extract reduced passage time of the blood obtained from disseminated intravascular coagulation model rats. In addition, the extract inhibited the reduction of platelets, which suggests that this attributed to the inhibition of platelet aggregation. The extract also demonstrated suppressive effects on both collagen-and arachidonic acidinduced platelet aggregation. Moreover, the extract showed inhibition against cyclooxygenase. The active principle was determined to be pterostilbene by collagen-induced platelet aggregation inhibitory activity-guided purification. Pterostilbene is a derivative of resveratrol, which is known to be in red wine and to possess beneficial effects for prevention of life-style related diseases. Pterostilbene exhibited 56 and 57% inhibition on both collagen-and arachidonic acidinduced platelet aggregation at 20 µM, respectively. These results demonstrate that the extract of PM heartwood may be a promising candidate as a multifunctional agent for treating lifestyle-related diseases.
Lifestyle-related diseases (LRD) have become main causes of death in Japan and the number of patients affected by LRD has increased approximately 10% in the past 3 years. LRD are a group of diseases caused by poor diet, lack of exercise and metabolic abnormality such as diabetes mellitus, hypertension, gout and hyperlipidemia [1] [2] [3] . Prevention is the only effective therapeutic strategy for LRD because a complete cure cannot be expected due to the lack of effective medication. From the preventive point of view, we considered consumption of functional and/or supplemental foods would be one effective strategy. Therefore, our research group has screened natural plant materials having inhibitory activity on xanthine oxidase, anti-benign prostate hyperplasia activity and improvement effects on blood fluidity. Among the materials screened, we discovered rhizomes of Kaempferia parviflora (Zingiberaceae) as an effective material due to its inhibitory activity on xanthine oxidase [4] , anti-benign prostate hyperplasia activity [5] and improvement effects on blood fluidity in disseminated intravascular coagulation (DIC) model rats [6] . We extended our research to Indian plants and focused on Pterocarpus marsupium (Indian kino tree) as another candidate.
The Indian kino tree (Asana, P. marsupium, PM) is a Fabaceae plant found in hilly regions throughout the Deccan Peninsula. In Ayurvedic folk medicine, water stored in a tumbler made of PM heartwood has been administered to the patients of diabetes mellitus as an effective agent. Extensive research has been performed to demonstrate the anti-diabetes activity of PM as Ahmad et al. reported that the ethyl acetate-soluble fraction obtained from PM ethanolic extracts had hypoglycemic effects based on blood insulin increasing activity in alloxan-induced diabetic rats [7] .
Manickam et al. identified marsupin and pterostilbene as the active principles with hypoglycemic activity in streptozotocin-induced diabetic model rats [8] . The state of hyperglycemia in diabetes mellitus leads to vascular endothelial damage related to vascular cells and/or tissue glycation, followed by thrombotic tendencies and deficiency in blood circulation.
Thus, diabetes mellitus is closely related with blood fluidity and bad blood fluidity would be a cause of LRD. In these circumstances, an agent possessing both anti-obesity effects and improvement effects on blood fluidity would be promising for the prevention of LRD. We expected that the heartwood of PM would be a suitable raw material for functional and/or supplemental foods. In this manuscript, effects on blood fluidity by PM were investigated and one of its active compounds has been determined.
To examine the effects of PM-ext on blood fluidity, we used LPSinduced DIC model rats according to the method of Schoendorf et al. [9] with a micro channel array flow analyzer (MC-FAN). Intravascular injection of LPS caused microvascular damage, resulting in hemorrhage. The coagulation cascade was activated by the hemorrhage to consume platelets and fibrinogen, followed by conversion of fibrinogen to fibrin. Then, the fibrin-degraded product (FDP) level was increased. As a result, blood fluidity was aggravated.
As shown in Table 1 , the injection of LPS (1 mg/kg, intravenously, i.v.) induced a systemic hemorrhagic disorder in DIC accompanied by decreases in the number of blood platelets and the amount of fibrinogen. In addition, the levels of FDP were increased. Table 1 .
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On the other hand, LPS injection and PM-ext administration showed no significant effects on the number of white and red blood cells (Table 1) .
To the best of our knowledge, we demonstrated for the first time that the oral administration of PM-ext improved blood fluidity and exhibited inhibitory activity on the platelet consumption in DIC model rats. In addition, these results suggested that the improvement activity on blood fluidity may be attributed to inhibitory activity of platelet aggregation.
To demonstrate the mechanism, we focused on the in vitro effects of PM-ext on rabbit platelet collagen-induced aggregation, thrombin activation and the fibrinolytic system. PM-ext concentrationdependently inhibited collagen-induced platelet aggregation, as shown in Table 2 and had no effect on thrombin activation or the fibrinolytic system (data not shown). Activity-guided fractionation PM-ext was carried out using in vitro collagen-induced rabbit platelet aggregation ( Figure 1 ). The PM-ext was fractionated by solvent extraction to give an ethyl acetate (AcOEt)-soluble fraction, butanol (BuOH)-soluble fraction and water-soluble fraction. The anti-platelet activity of 3 fractions at 200 µg/mL was evaluated, and the AcOEt-soluble fraction, BuOH-soluble fraction and watersoluble fraction showed 53, 20 and 3% inhibition, respectively. The AcOEt-soluble fraction demonstrated the most potent activity among them. Male Std-JW/CSK rabbits (13 weeks of age) were used for experiment. Platelet aggregation was induced by 5 µg/mL collagen. Each value represents the mean ± S.D. of 3 experiments. Significantly different from the control group, **: p<0.01.
The AcOEt-soluble fraction was subjected to silica gel column chromatography to give 5 fractions (Fr. A~E) according to the TLC analysis. The anti-platelet activities of fractions at 50 µg/mL were assayed and Fr. B showed the most potent activity of 54% inhibition. From HPLC analysis of Fr. B, only pterostilbene was detected ( Figure 2 ). To evaluate the inhibitory activity of pterostilbene on rabbit platelet collagen-induced aggregation, we compared the activity with that of resveratrol. Resveratrol is known as one of the potent platelet aggregation inhibitors [10] and also known as a material for health food. Pterostilbene exhibited 91% inhibition at 50 μM while resveratrol showed 84% at the same concentration. In addition, pterostilbene demonstrated higher potency in lower concentrations at 5 and 20 μM, i.e. pterostilbene showed 31 and 56% inhibition while resveratrol showed 3 and 26% inhibition at 5 and 20 μM, respectively. These results suggest that pterostilbene is more effective on collagen-induced platelet aggregation inhibition.
The platelet aggregation mechanism has a cascade reaction. adenosine 5'-diphosphate (ADP) and arachidonic acid are the main factors in the platelet aggregation cascade. To elucidate the details of the inhibitory mechanism of platelet aggregation by pterostilbene, we examined the inhibitory activity of pterostilbene and resveratrol on rabbit arachidonic acid-and ADP-induced platelet aggregation. In the arachidonic acid-induced platelet aggregation assay, pterostilbene and resveratrol exhibited 57 and 67% inhibition at 50 μM, respectively (Table 3) . However, both compounds had no effect on ADP-induced platelet aggregation at 100 μM.
Cyclooxygenase is a one of the rate-limiting enzymes that activate platelets by producing prostaglandins from arachidonic acid. Two distinct COX isoforms are known, COX-1 and COX-2 [11] , and more recently a third form, COX-3 [13] . COX-1 is expressed constitutively in many cells where it produces the prostaglandins and is involved platelet activation. It is well known that COX inhibitors suppress the platelets aggregation [14] . Hougge et al. reported that COX-2 was inhibited selectively by P. marsupium extract and pterostilbene with COX whole blood assay [15] . To confirm the COX inhibitory activity of pterostilbene, inhibitory activity of pterostilbene and resveratrol on COX-1 and COX-2 was investigated using a COX Activity Assay Kit [16] with modifications [17] . As a result, PM-ext showed 94 and 85% inhibition at 100 μg/mL against COX-1 and -2, respectively (Tables   4 and 5 ). These results demonstrated that PM-ext had moderate activity on both COXs, but no significant selectively was observed. Pterostilbene exhibited 59 and 24% inhibition at 50 μM against COX-1 and -2, respectively. These results suggest that pterostilbene had relatively high selectivity compared with PM-ext, suggesting that other active compounds may be contained in PM-ext. Resveratrol showed 100 and 68% inhibition at 50 μM against COX-1 and -2, respectively. These potencies were higher than those of pterostilbene at p value of 0.01, respectively. However, the selectivity of resveratrol was lower than that of pterostilbene even though they share a similar chemical skeleton.
Interestingly, pterostilbene showed more potent activity than resveratrol at 20 µM on anti-platelet aggregation. However, resveratrol has more potent inhibitory activity on COX-1 than pterostilbene at 20 µM. The reasons for these results is still yet to be revealed. We can hypothesis that pterostilbene may be easily pass the membrane of the platelets compared to resveratrol due to its low polarity. In arachidonic acid pathway, COX produces prostaglandin (PG) H 2 from arachidonic acid as the rate-limiting enzyme. Then, PGH 2 will be converted to eicosanoids including thromboxane (TX) A 2 , which is one of the platelet activators. Pterostilbene also may have inhibitory activity through TXA 2 production. On the other hand, TXA 2 is known as a platelet activator as well as ADP and serotonin (5-HT, 5-hydroxytryptamine). Pterostilbene also may have anti-platelet aggregation through the serotonin pathway.
As shown in Table 3 and 4, pterostilbene showed more potent inhibitory activity on collagen-induced platelet aggregation than arachidonic acid-induced aggregation at 20 µM. Although resveratrol has lower activity on collagen-induced than arachidonic acid-induced platelet aggregation. These results may indicate that resveratrol enhances platelet aggregation induced by collagen in some extent.
In conclusion, to the best of our knowledge, this is the first report of in vivo preventive effects of PM-ext on blood fluidity aggravation and in vitro anti-COX activity. In addition, anti-platelet aggregation and anti-COX activity of pterostilbene was found. These results demonstrate that PM-ext may have improvement effects for both diabetes and its complication, aggravation of blood fluidity. This is the most characteristic feature of PM-ext and PM-ext would be a valuable raw material for supplemental or functional food targeting diabetes. Further studies to determine other active principles are now underway in our laboratory.
Experimental
Reagents: Reagents used in this study were purchased from Wako Pure Chemicals (Osaka, Japan), Nacalai Tesque (Kyoto, Japan) or Sigma-Aldrich (St. Louis, MO, USA), unless otherwise stated.
Preparation of extracts from heartwood of P. marsupium: Heartwood of P. marsupium was obtained from INABATAKORYO CO., LTD. on May 2014. The pulverized heartwood (400 g) was extracted with 50% ethanol (EtOH, 4 L) under reflux for 2 hours. The filtrates were combined and the solvent was evaporated under reduced pressure and lyophilized to give brown powder (PM-ext, 46.4 g, 11.6%).
Animals:
Male Std-Wistar/ST rats (7 weeks of age) and male Std-JW/CSK rabbits (13 weeks of age) were purchased from Japan SLC (Shizuoka, Japan). They were maintained in an air-conditioned room with lighting from 07:00 a.m. to 07:00 p.m. The room temperature (approximately 23ºC) and humidity (approximately 60%) were controlled automatically. Laboratory pellet chow (for rats: Labo MR stock, Nihon Nosan Kogyo Co., Ltd., Tokyo; for rabbits: RC-4, Oriental Yeast Co., Ltd., Tokyo) and water were freely available. All experimental protocols were approved by the Committee for the Care and Use of Laboratory Animals at Kindai University (Protocol numbers: KAPS-20-015, KAPS-20-016 and KAPS-20-028).
Lipopolysaccharide-induced DIC test: Lipopolysaccharide (LPS, purified by phenol extraction)-induced DIC rats were prepared according to the method of Schoendorf et al. with minor modifications. Each PM-ext (50, 200 and 500 mg/kg) suspended in 0.2% carboxymethylcellulose sodium aqueous solution (CMC) was administered orally to rats in the respective groups once a day for 7 successive days (Day 1-7) . On Day 7, LPS (1 mg/kg, dissolved in saline) was injected into the tail vein of rats of the vehicle control, PM-ext and heparin groups 1 hour after sample administration. CMC was administered orally to the control group and the vehicle control group rats once a day for 7 successive days (Day 1-7) . Heparin (500 U/kg, dissolved in saline), a reference drug, was administered by injection to the tail vein of rats of the heparin group 1 hour before the injection of LPS on Day 7. Blood samples in duplicate were withdrawn from the abdominal vein into plastic syringes 4 hours after the injection of LPS while the animals were anesthetized with pentobarbital (35 mg/kg, intraperitoneally, i.p.). Each blood sample was measured for the following parameters by Osaka Kessei Research Laboratories (Osaka, Japan): fibrinogen, fibrin degradation products (FDP) and platelet counts. Using another whole blood sample, blood passage time, the time taken for the passage of 50 µL of the mixture (1.8 mL of blood and 0.2 mL of 3.8% sodium citrate solution), of each group (control, vehicle control, PM-ext and heparin group) was measured by a micro channel array flow analyzer (MC-FAN, Hitachi, Tokyo) with a micro channel array Bloody 6-5 (the array has 8,736 parallel slits: size of each slit; 4.5 µm wide, 30 µm long, 4.5 µm deep). The whole blood passage time was determined under a negative pressure of 20 cm of water. The standard passage time required for passage of 100 µL of saline through the micro channel array was 14.0 sec. In order to avoid deviation in the micro channel array, the saline passage time required for 100 µL of saline was determined just before each blood sample measurement. The whole blood passage time for 50 µL of the mixture was calculated from the following equation:
Whole blood passage time (s) = observed whole blood passage time (s) ×14.0 (s)/ observed saline passage time (s).
Fractionation of PM-ext:
The PM-ext (8 g) was suspended in water (48 mL) and extracted with AcOEt (24 mL x 2). The water was then extracted with BuOH (24 mL x 2). The yields of AcOEt, BuOH and water fractions were 2.95 g, 1.69 g and 3.29 g, respectively. The AcOEt-soluble fraction (2.95 g) was subjected to silicic gel column chromatography (280 g, Merck, 2. 
Measurement of platelet aggregation:
Whole blood samples were collected from a rabbit heart. Nine mL of blood and 1 mL of sodium citrate (3.8%) aqueous solution were placed in a plastic tube, and centrifuged at 170×g for 10 min at 25°C to obtain a platelet-rich plasma (PRP). The PRP was removed with a siliconized pipet and stored in another plastic tube with a screw cap. The remaining red cell precipitate of the blood samples was further centrifuged at 1,520×g for 15 min at 25°C to give platelet poor plasma (PPP), which was used as a maximal transmittance standard. A platelet suspension solution was diluted with PPP to a concentration range of 2.5-3.5×10 5 platelets/µL. In vitro platelet aggregation was measured according to the method of Born et al. [18] with minor modifications. The test sample was dissolved with dimethyl sulfoxide (DMSO) and diluted with 50 mM Tris-HCl buffer (adjusted to pH 7.4 with 1 M HCl) to a final DMSO concentration of 0.5% v/v. As a control, 0.5% DMSO in 50 mM Tris-HCl buffer was used. Two hundred µL of PRP was placed in an aggregometer cuvette (PRP 313M, MC Medical Inc., Tokyo), and was stirred at 1,000 rpm for 3 min at 37°C, and then 11 µL of a test solution was added. After 3 min, 11 µL of collagen solution, as an aggregation agent solution (final concentration: 100 µg/mL collagen diluted with attached solution for dilution, 100 µM adenosine diphosphate diluted with distilled water or 10 µg/mL arachidonic acid diluted with 30% DMSO/buffer), was added to the reaction mixture. Changes in the transmittance of the reaction mixture were recorded for 10 min by an aggregometer, and the maximal transmittance was measured after the addition of collagen solution. Platelet aggregation (%) was expressed as an increase in maximal transmittance (%). The levels of transmittance were calibrated as 0% for the PRP suspension and as 100% for the PPP solution. Indomethacin was used as a reference drug. Platelet aggregation (%) was expressed as an increase in maximal transmittance (%). The levels of transmittance were calibrated as 0% for the PRP suspension and as 100% for the PPP solution. Indomethacin and adenosine were used as reference drugs. Platelet aggregation inhibition (%) of each sample was expressed as percentage of the decrease in maximal transmittance compared with that of the control.
Fibrin plate assay: Fibrinolysis activity in vitro was evaluated according to the method of Murata et al. [19] .
Thrombin-induced fibrinogen coagulation test: Fibrinogen (500 mg) was dissolved in 100 mL of 0.5 M Tris-acetate buffer (pH 7.4) in 0.15 M NaCl. The test sample was dissolved with DMSO and diluted with Tris-acetate buffer to a final DMSO concentration of 5.0% v/v. A test solution (0.1 mL) was added to 1.8 mL of a fibrinogen solution with stirring. After 1 min, 0.1 mL of thrombin solution (0.2 U/ mL) was added and the whole solution was gently stirred until a fibrin clot appeared. The time required for clotting was recorded.
Assay of inhibitory activity against cyclooxygenase (COX):
Cyclooxygenase inhibitory activity was evaluated calorimetrically by monitoring the appearance of oxidized N, N, N, N-tetramethyl-pphenylenediamine (TMPD) at 590 nm. The test sample was dissolved with DMSO. COX was also diluted with Assay buffer (100 mM Tris-HCl buffer, pH 8.0) to 4-times the volume. Then, 10 µL of sample solution, 20 µL of COX solution and 10 µL of heme (100 µM) were added to 150 µL of Assay buffer on the 96-well plate. The mixture was pre-incubated at 25ºC for 5 min. Twenty µL of TMPD solution and 20 µL of arachidonic acid (100 µM) were added to the reaction. After incubation at 25ºC for 2 min, the amount of oxidized TMPD in the mixture was measured based on the optical density (OD) at 590 nm using a microplate reader (Sunrise R, Tecan, Männedorf, Switzerland). DuP-697 and SC-560 were used as standard agents for COX-1 and COX-2, respectively. Where A is the OD at 590 nm with enzyme, but without test substance; B the OD at 590 nm without test substance or enzyme; C the OD at 590 nm with test substance and enzyme; and D the OD at 590 nm with test substance, but without enzyme.
Statistical analysis:
Results are expressed as the mean ± S.D. Significant differences were detected using a multiple comparison test with the Bonferroni/Dunn algorithm (Statcel3, OMS Publishing, Tokyo, Japan) at p< 0.01 and p< 0.05.
